J&J presents positive new efficacy and safety data for Invokana

15 April 2019

Johnson & Johnson (NYSE: JNJ) has unveiled positive Phase III data from the CREDENCE study of Invokana (canagliflozin) at the World Congress of Nephrology in Australia.

The test group achieved a 30% risk reduction for the composite primary endpoint. The trial is comparing Invokana, for which Mundipharma is the exclusive European Union distributor, with placebo in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), when used in addition to standard of care.

The therapy also reduced the risk of secondary cardiovascular (CV) endpoints, including the risk of CV death and hospitalization for heart failure by 31%, major adverse CV events by 20%, and the risk of hospitalization for heart failure alone by 39%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK